Denovicon addresses drug discovery challenges related to drug candidates’ ADME, pharmacokinetic and toxicological properties.
The company has developed a physics-driven generative AI platform using multi-objective optimization to evaluate target engagement, potency, selectivity, ADMET properties and synthesizability across large molecule spaces. Denovicon’s internal programs focus on small-molecule therapeutics targeting DNA damage response pathways, including PARP1, PARP2 and PARP7.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
Denovicon works with pharmaceutical companies and biotechnology companies.
The platform uses multi-objective optimization to evaluate target engagement, potency, selectivity, ADMET properties and synthesizability across trillion-molecule spaces.
Source: LinkedIn company description · Retrieved October 13, 2026
The company’s internal programs include small-molecule therapeutics targeting DNA damage response pathways, including PARP7.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Open the published source list.RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 10, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.